| Previous Close | 56.33 |
| Open | 56.45 |
| Bid | 31.64 x 300 |
| Ask | 0.00 x 0 |
| Day's Range | 56.18 - 56.98 |
| 52 Week Range | 37.35 - 60.00 |
| Volume | 580,574 |
| Avg. Volume | 871,157 |
| Market Cap | 5.01B |
| Beta | 1.55 |
| PE Ratio (TTM) | -22.51 |
| EPS (TTM) | -2.52 |
| Earnings Date | Oct 31, 2017 - Nov 6, 2017 |
| Dividend & Yield | 0.00 (0.00%) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 73.33 |
Markit•3 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- PR Newswire•6 days ago
Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress
SAN DIEGO, Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the RE-KINECT study outlining the real-world presence and impact of tardive dyskinesia (TD) on the lives of both patients and caregivers. "This year's Psych Congress serves as an excellent opportunity to dive deeper into the patient impact of TD, including demographics and healthcare utilization. The RE-KINECT study provides valuable insight into the complexities and needs of these patients and how INGREZZA can address the movements that may disrupt patient lives," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine.
Markit•10 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
